Moderna, Inc. Common Stock

MRNA XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

18B

Short interest (May 15)

14.6%

Net Short (Jun 03 ): 0.1%

Borrow Fee

0.38%

↓ 9.9%

Available Shares

↓ 4.2%

Price Chart

Company Overview

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001682852

Asset Type: CS

Market Data

Market Cap: $18,109,324,860

Employees: 4,700

Status: Active

Short Interest

Current Borrow Fee 0.38%

Range: 0.29% - 0.39%

Available Shares 3M

Range: 2.6M - 3M

Recent Changes

Fee Change: ↑ 8.5%

Available Change: ↓ 13.7%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime